Chronic Kidney Disease Market: 5 Emerging Therapies to Watch as the Treatment Landscape Expected to Evolve by 2036 | DelveInsight

lorundrostatMZE829rilparencelPositive

AI Analysis

Summary

A market analysis report highlights five emerging therapies in development for chronic kidney disease, including endothelin receptor antagonists, aldosterone synthase inhibitors (lorundrostat), APOL1 inhibitors (MZE829), and cell therapy (rilparencel), expected to reshape the treatment landscape by 2036.

Importance:2/10

Sentiment:

0.30

Chronic Kidney Diseaselate-stage pipelineendothelin receptor antagonistsaldosterone synthase inhibitorsAPOL1 inhibitorscell therapymarket analysis

Related Companies

$DHCNL

Read the original article

Published by PR Newswire Pharma on September 24, 2026 2:31 PM

Read Original